• 검색 결과가 없습니다.

One-Year Open-Label Study of Entacapone in Patients with Advanced Parkinson Disease

N/A
N/A
Protected

Academic year: 2021

Share "One-Year Open-Label Study of Entacapone in Patients with Advanced Parkinson Disease"

Copied!
4
0
0

로드 중.... (전체 텍스트 보기)

전체 글

Loading

참조

관련 문서

Results: In this research, in the group with fibromyalgia patients group, systemic lupus erythematosus patients group and without systemic autoimmune

surveillance study of patients with Emergency Department injuries under the control of the Korea Centers for Disease Control and Prevention (KCDC).Statistical

Higher open conversion rate and prolonged postoperative hospital stay in LATE group were not caused by the delayed operation in this study it seems to be caused by that

In conclusion, as the TDRD7 gene expression levels of the cataract patients found in the test conducted for 70 objects living in local region in this

However, the present study showed that four components of the BSS (cough, sputum, dyspnea, and chest pain) were improved more with HL301 treat- ment than with placebo

Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including

and V005: kidney transplant, KT) provided by the Korean government. Patients with less than 3 months of dialysis history and those who changed dialysis modality were excluded.

Our study showed comparable success rates between Ahmed valve implantation with MMC and trabeculectomy with MMC in patients with uveitic glaucoma throughout the